Penn spinout ViTToria Biotherapeutics secured over $15 million in a private financing round. The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, a CAR-T cell therapy for T-cell Lymphoma, into the clinic.
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from Penn, the company’s proprietary Senza5 platform, which is designed to improve the efficacy of engineered T cell therapies with pipeline applications in oncology and autoimmune diseases.Read more about ViTToria and its recent funding here.